Keystone Symposia Conference | Molecular and Cellular Biology of Immune Escape in Cancer

Meeting Program

To view program in "24 hour" time (international) click here.

Sunday, February 7
3:00 - 7:30 PM	Registration	Longs Peak Foyer
6:30 - 7:30 PM	Refreshments	Longs Peak Foyer
7:30 - 9:30 PM	Keynote Session (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays/Longs Peak
	* Nina Bhardwaj, New York University School of Medicine, USA
	* Dmitry I. Gabrilovich, University of South Florida, USA
	* George C. Prendergast, Lankenau Institute for Medical Research, USA
	* Giorgio Trinchieri, National Cancer Institute at Frederick, USA
	Robert D. Schreiber, Washington University School of Medicine, USA Co-Evolution of Immunoediting on Oncogenesis during Tumor Formation
	Frances R. Balkwill, Queen Mary University of London, Barts and The London Medical School, UK Inflammatory Cytokines and Autocrine Tumor-Promoting Networks
Monday, February 8
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Tumor Microenvironment and Immune Escape (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: This session will be focused on how stromal cells, inflammation, and angiogenesis support malignant progression, highlighting crucial roles for immune cells in contributing to these processes.	Grays/Longs Peak
	* Robert D. Schreiber, Washington University School of Medicine, USA
	Lisa M. Coussens, University of California, San Francisco, USA Role of Inflammation in Tumor Progression
	Claire E. Lewis, University of Sheffield Medical School, UK Role of Macrophages in Tumor Progression and Response to Therapy
	Arya Biragyn, National Institute of Aging, National Institutes of Health, USA Short Talk: Primary Breast Cancer Actively Generates Regulatory T and B Cells (Tregs and Bregs) to Facilitate Lung Metastasis
	Gerard I. Evan, University of California, San Francisco, USA Immune Function and Angiogenesis in Myc-mediated Tumor Formation
	Hans Schreiber, University of Chicago, USA The Role of Tumor Stroma in Immune Escape of Cancer
	Alexander J. Muller, Lankenau Institute for Medical Research, USA Short Talk: IDO Contributes to Pathologies Associated with Chronic Inflammation
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM-	On Own for Lunch and Recreation
11:15 AM- 1:00 PM	Poster Setup	Quandary
1:00 - 10:00 PM	Poster Viewing	Quandary
2:30 - 4:30 PM	Workshop 1: Regulation of Immune Escape by Microenvironment NOTE: This session will deepen understanding of the critical role of the tumor microenvironment in driving malignant progression.	Longs Peak
	* Dmitry I. Gabrilovich, University of South Florida, USA
	Esteban Celis, Moffitt Cancer Center, USA Interferon-gamma Induced T Cell Epitope Purging: Another Mode of Tumor Immune Escape?
	Cassie K. Chou, University of Washington, USA Abrogation of TGFbeta Signaling Leads to Increased Persistence of Prostate Self/Tumor Antigen Specific CD8 T Cells but does not Completely Prevent Tolerization
	Stephanie Watkins, National Cancer Institute, National Institutes of Health, USA Prostate Tumor-Associated Dendritic Cell Induction of Tolerance and Suppressor Activity in Tumor-Infiltrating CTLs is Associated with FOXO3a Expression
	Courtney Smith, Lankenau Institute for Medical Research, USA Indoleamine 2,3-Dioxygenase (IDO) Supports Metastatic Outgrowth of the 4T1 Breast Cancer Mouse Model
	Sheng Wei, Moffitt Cancer Center, USA Myeloid-Derived Suppressor Cells (MDSC) are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS)
	Michael S. Leibowitz, University of Pittsburgh, USA TAP1/2 Downregulation and CTL Evasion is Independent of STAT3 Activation in Head and Neck Cancer Cells
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Antigen-Specific Mechanisms of Tumor Escape Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: This session will be focused on molecular and cellular mechanisms associated with role of antigens in tumor escape. Topics include tumor antigen diversity, molecular mechanisms of defective antigen presentation by tumor cells, dendritic cells and T cell tolerance.	Longs Peak
	* Hans Schreiber, University of Chicago, USA
	Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany No Escape
	Hyam I. Levitsky, Johns Hopkins School of Medicine, USA Mechanism of T-Cell Tolerance in Cancer
	Richard A. Flavell, Yale University School of Medicine, USA TGF-beta Signaling in Tumoral Immune Suppression
	Andrew D.M. Kaiser, Netherlands Cancer Institute, The Netherlands Short Talk: Low Tumor-Antigen Density Leads to PD-L1/PD-1 Mediated Suppression of Partially Exhausted CD8+ T Cells
Following Session is for Cancer and Inflammation (J5)
5:00 - 7:00 PM	Inflammation in the Tumor Microenvironment Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays Peak
	* Frances R. Balkwill, Queen Mary University of London, Barts and The London Medical School, UK


	Alberto Mantovani, Istituto Clinico Humanitas, Italy Tumor Microenvironment: Sculpting the Inflammatory Response during Tumor Formation
	Susan E. Erdman, Massachusetts Institute of Technology, USA Unifying Roles for Regulatory T Cells and Inflammation in Cancer
	Li Yang, National Cancer Institute, National Institutes of Health, USA Short Talk: TGFbeta, an Inflammation and Immune Suppressor in Tumor Progression
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Quandary
Tuesday, February 9
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Myeloid Cells in Immune Suppression and Tumor Progression Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: This session will focus on the molecular and cellular mechanisms of immunosuppression by different types of myeloid cells.	Longs Peak
	* Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori, Italy
	Dmitry I. Gabrilovich, University of South Florida, USA Regulation of Myeloid-Derived Suppressor Cells in Cancer
	Suzanne Ostrand-Rosenberg, University of Maryland, USA Myeloid Cells, Inflammation, and Anti-Tumor Immunity: Not an Auspicious Combination
	David R. Gibb, Virginia Commonwealth University, USA and
	Sheinei Jamal Saleem, Virginia Commonwealth University, USA Short Talk: A Novel Model of Myeloid-Derived Suppression of the Anti-Tumor Response: Overexpression of ADAM10 Promotes Myeloid-Derived Suppressor Cell Expansion in a Tumor-Free Environment
	Vincenzo Bronte, Istituto Oncologico Veneto, Italy Forced Myelopoiesis and Immune Deviation in Cancer
	Ling Qi, Cornell University, USA Short Talk: The Metabolic Function of Myeloid-Derived Suppressor Cells in Obesity
	Cong Yan, Indiana University School of Medicine, USA Short Talk: Apoptotic Inhibition of Myeloid Cells Causes MDSC Expansion and Lung Tumorigenesis
	Anna Wasiuk, Dartmouth College, USA Short Talk: Mast Cells as Regulators of Adaptive Immunity to Tumors
Following Session is for Cancer and Inflammation (J5)
8:00 - 11:15 AM	Inflammation and Carcinogenesis Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays Peak
	* Alberto Mantovani, Istituto Clinico Humanitas, Italy

	Eva M. Hernando, New York University Cancer Center, USA miRNAs that Contribute to Melanoma Metastasis by Modulating Immune Evasion
	Yinling Hu, National Cancer Institute at Frederick, USA Role of IKKalpha in Skin Cancer
	Pauline M. Andreu, University of California San Francisco, USA Short Talk: FcRgamma Activation Regulates Inflammation-Associated Squamous Carcinogenesis
	Giorgio Trinchieri, National Cancer Institute at Frederick, USA Innate Resistance and Cancerogenesis

	Carlos Bais, Genentech, Inc., USA Stromal Cells and VEGF-Independent Angiogenesis
	Brendan J. Jenkins, Monash Institute of Medical Research, Australia Short Talk: Deregulated Cytokine Signaling as a Crucial Bridge Linking Pathogen-Driven Gastric Inflammation and Tumorigenesis
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM-	On Own for Lunch and Recreation
11:15 AM- 1:00 PM	Poster Setup	Quandary
1:00 - 10:00 PM	Poster Viewing	Quandary
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Regulatory T and NKT Cells in Immune Escape Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: This session is focused on molecular and cellular mechanisms of regulatory T cell function in cancers. Specific topics can include novel findings on the role of classical Treg in cancer, different types of Tregs, and role of NKT.	Longs Peak
	* Vincenzo Bronte, Istituto Oncologico Veneto, Italy
	Harald von Boehmer, Harvard Medical School, USA In vivo Induction of Antigen-Specific Regulatory T Cells to Prevent Unwanted Immunity
	Rong-Fu Wang, Baylor College of Medicine, USA Immunosuppressive gammadelta Treg and other Immune Cells and their Functional Regulation through Innate Immune Signaling
	Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori, Italy OX40 Costimulation in Treg Functions
	Jay A. Berzofsky, National Cancer Institute, National Institutes of Health, USA Short Talk: Tipping the Balance in the NKT Cell Regulation of Tumor Immunity
Following Session is for Cancer and Inflammation (J5)
5:00 - 7:00 PM	Innate Resistance and Tumor Escape Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays Peak
	* Nina Bhardwaj, New York University School of Medicine, USA
	David H. Raulet, University of California, Berkeley, USA NKG2D, NKG2D Ligands and Spontaneous Malignancy
	Laurence Zitvogel, Institut Gustave Roussy, France NKp30/NCR3 Isoforms and Prognosis of Human Malignancies: Revisiting the DC/NK Cross Talk
	Mark J. Smyth, Peter MacCallum Cancer Centre, Australia Suppression and Innate Immune Surveillance
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Quandary
Wednesday, February 10
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Transcriptional Regulation of Immune Escape (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: Session will discuss regulation of gene expression implicated in tumor progression and immune escape, including possible modifier effects and relationship to metastastic efficiency.	Grays/Longs Peak
	* George C. Prendergast, Lankenau Institute for Medical Research, USA
	Hua E. Yu, Beckman Research Institute, City of Hope, USA STATs in Cancer Inflammation and Immune Escape: A Leading Role for Stat3
	Erwin F. Wagner, Spanish National Cancer Research Centre, Spain Functions of AP-1 (Fos/Jun) in Inflammation and Cancer
	Mitsugu Fujita, University of Pittsburgh Cancer Institute, USA Short Talk: Type-1 Interferons Play a Pivotal Role in Anti-glioma Immunosurveillance
	Thomas F. Gajewski, University of Chicago, USA T Cell Dysfunction in the Tumor Microenvironment as a Mechanism of Tumor Escape
	Michael Karin, University of California, San Diego, USA NF-kappaB in Inflammation, Progression and Immune Response
	Jahan Khalili, MD Anderson Cancer Center, USA Short Talk: The Role of B-raf V600E Mutation on PD-1 Ligand Expression in Melanocytic nevi
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM-	On Own for Lunch and Recreation
11:15 AM- 1:00 PM	Poster Setup	Quandary
1:00 - 10:00 PM	Poster Viewing	Quandary
2:30 - 4:30 PM	Workshop 2: Tumor Recruitment of Immune Cells: Roles in Tumor Progression and Immune Escape NOTE: Consider roles for MDSCs, B cells, mast cells, microvesicle transfer, etc.	Longs Peak
	* Michael R. Shurin, University of Pittsburgh, USA
	Philippe Foubert, University of California, San Diego, USA Blockade of Myeloid Cell Trafficking by Inhibiting a PI3-Kinase gamma-alpha4 Integrin Activation Pathway Stimulates Anti-Tumor Immunity
	Srinivas Nagaraj, University of South Florida, College of Medicine, USA Regulation of Myeloid-Derived Suppressor Cell Activity in Cancer by CD4+ T Cells
	Melody A. Swartz, Swiss Federal Institute of Technology (EPFL), Switzerland Lymph Node Mimicry by Tumors Promotes Immunological Tolerance
	Luca Vago, IRCCS H San Raffaele, Italy Loss of Mismatched HLA as a Mechanism of Leukemia Immune Escape in Family Haploidentical and Unrelated HSCT
	Rongcun Yang, Nankai University, China Suppressor of Cytokine Signaling-3 (SOCS3) Downregulates the Ability of Pyruvate Kinase Type M2 to Cause Dendritic Cell Dysfunction
	George Coukos, University of Pennsylvania, USA Hypoxia Recruits Regulatory T Cells via the CCL28 Chemokine to Promote Tolerance and Angiogenesis in Cancer
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Immune Inhibitory Receptors in Cancer Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Longs Peak
	* Augusto C. Ochoa, Louisiana State University Health Sciences Center, USA
	Lieping Chen, Johns Hopkins School of Medicine, USA Co-Stimulatory Control of Tumor Immunity and Autoimmunity
	Drew M. Pardoll, Johns Hopkins School of Medicine, USA Mechanism of T-Cell Tolerance in Cancer Mediated by Inhibitory Receptors
	Michael R. Shurin, University of Pittsburgh, USA Dendritic Cells in Immune Escape in Cancer
	Daniel Hirschhorn-Cymerman, Memorial Sloan-Kettering Cancer Center, USA Short Talk: OX40 Engagement and Chemotherapy Combination Provides Potent Anti-Tumor Immunity with Concomitant Regulatory T Cell Apoptosis
Following Session is for Cancer and Inflammation (J5)
5:00 - 7:00 PM	Innate Receptors, Cancer and Inflammation Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays Peak
	* Mark J. Smyth, Peter MacCallum Cancer Centre, Australia

	Xiaoxia Li, Cleveland Clinic Foundation, USA SIGIRR-Mediated Tumor Suppression
	Felix Yarovinsky, University of Texas Southwestern Medical Center, USA Short Talk: A Novel Transgenic Mouse Model for Chronic Inflammation: Linking Toll-like Receptor (TLR) Responses with Carcinogenesis

	Nina Linde, German Cancer Research Center (DKFZ), Germany Inflammation in Epithelial Skin Tumors

	Irving Coy Allen, University of North Carolina at Chapel Hill, USA Short Talk: NLRP3 is an Essential Regulator of Interleukin-1beta and Interleukin-18 during Inflammation Driven Colon Tumorigenesis
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary
7:30 - 10:00 PM	Poster Session 3 Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Quandary
Thursday, February 11
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Metabolic Pathways Involved in Immune Escape Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: This session will be focused on the role of metabolism of carbohydrates, lipids, arginine, tryptophan, and exosomes in tumor escape.	Longs Peak
	* Drew M. Pardoll, Johns Hopkins School of Medicine, USA
	David H. Munn, Medical College of Georgia, USA Indoleamine 2,3-Dioxygenase in Tumor Immune Escape
	Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental, Argentina 'Turning Sweet' on Immunity: Galectin-Glycan Interactions in T-Cell and Dendritic Cell Physiology
	Linglin Yang, University of Maryland, Baltimore County, USA Short Talk: Indoleamine 2,3-Dioxygenase (IDO) Contributes to Myeloid-Derived Suppressor Cell- Mediated Tumor Suppression through Interleukin-6 Signaling Pathway
	Augusto C. Ochoa, Louisiana State University Health Sciences Center, USA Arginine Depletion by MDSC in vivo, a Mechanism of Tumor Escape
	Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori, Italy Tumor-Derived Microvesicles and Immune Defects in Human Cancer
	Jonathan D. Silk, University of Oxford, UK Short Talk: A Novel Amino Acid Transporter Induced by Expression of Indoleamine 2,3 Dioxygenase in Tumors
Following Session is for Cancer and Inflammation (J5)
8:00 - 11:00 AM	Dendritic Cells and Macrophages in Cancer Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays Peak
	* Laurence Zitvogel, Institut Gustave Roussy, France
	Nina Bhardwaj, New York University School of Medicine, USA Modulating Inflammatory Dendritic Cell Responses against Cancer
	Shannon J. Turley, Dana Farber Cancer Institute, Harvard Medical School, USA Novel Aspects of Tolerance in the Tumor Microenvironment


	Miriam Merad, Mount Sinai Medical Center, USA Functional Diversity of Tumor Infiltrating Dendritic Cells
	Ana Carrizosa Anderson, Harvard Medical School, USA New Roles for TIM Family Members in Immune Regulation
	Emmanuelle Godefroy, New York University, School of Medicine, USA Short Talk: MMP-2 Conditions Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12 and OX40L-Dependent Pathway
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM-	On Own for Lunch and Recreation
2:30 - 4:30 PM	Workshop 3: Novel Strategies to Reverse Immune Escape in Cancer NOTE: Will discuss novel approaches to reversal of immune defects in cancer. Topics may include cytokines supporting productive immune response, block of inhibitory cytokines and receptors, regulation of immune responses via toll-like receptors, etc.	Longs Peak
	* Elizabeth M. Jaffee, Johns Hopkins University, USA
	Juan R. Cubillos-Ruiz, Dartmouth Medical School, USA siRNA Delivery through Novel TLR5-Agonist Polyethylenimine Reprograms Tumor-Associated Regulatory Dendritic Cells to Elicit Therapeutic Immunity
	Viktor Umansky, German Cancer Research Center, Germany Blocking of Myeloid Derived Suppressor Cell (MDSC) Functions Results in Antitumor Effects in Ret Transgenic Mouse Melanoma Model
	Xiangdong Liu, Incyte Corporation, USA INCB24360, a Potent and Selective Inhibitor of Indoleamine 2,3-dioxygenase (IDO) for Cancer Immunotherapy
	Ge Ma, Mount Sinai School of Medicine, USA Paired Immunoglobin Like Receptor-B (PIRB) Regulates the Suppressive Function and M1 versus M2 Differentiation of MDSC
	Carl E. Ruby, Earle A. Chiles Research Institute, USA Characterizing the Effect of Aging in Tumor-Bearing Hosts Treated with OX40 Agonists
	Thorbald van Hall, Leiden University Medical Center, The Netherlands A Novel Category of Tumor Antigens Enable CTL Immunity to Tumor Escape Variants
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:15 PM	Therapeutic Development to Correct Immune Escape in Cancer Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010 NOTE: This session will discuss preclinical and clinical development of different approaches to counter immune suppressive mechanisms in cancer.	Longs Peak
	* Hyam I. Levitsky, Johns Hopkins School of Medicine, USA
	George C. Prendergast, Lankenau Institute for Medical Research, USA Regulation and Therapeutic Inhibition of IDO/IDO2 in Cancer
	Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, USA Therapeutic Regulation of Immune Responses in Cancer Patients Using CTLA-4 Antibodies
	Elizabeth M. Jaffee, Johns Hopkins University, USA Vaccine Induced Immune Responses and the Pancreatic Tumor Microenvironment
	Jeffrey Weber, H. Lee Moffitt Cancer Center, USA Regulation of Immune Responses in Cancer via Checkpoint Blockade of Negative Receptors in Melanoma
Following Session is for Cancer and Inflammation (J5)
5:00 - 7:00 PM	Cytokines in the Tumor Microenvironment Registered attendees for this meeting can view Abstracts for this session starting on 01/07/2010	Grays Peak
	* Giorgio Trinchieri, National Cancer Institute at Frederick, USA
	Jacqueline Bromberg, Memorial Sloan Kettering Cancer Center, USA The IL-6/Stat3 Signaling Pathway Promotes Mammary Tumorigenesis and Metastases
	Martin Oft, Merck, USA Switching Tumor Promoting Inflammation into Tumor Immune Surveillance
	Charles Drake, Johns Hopkins University, USA Th17 Cells in Tumors
	Jiyoung Park, University of Texas Southwestern Medical Center, USA Short Talk: Peripheral Leptin Promotes Mammary Tumor Progression and Metastasis through Activation of the Jak2/STAT3 Pathway in vivo
7:15 - 8:15 PM	Social Hour w/ Lite Bites	Quandary
8:15 - 11:00 PM	Entertainment	Quandary
Friday, February 12
	Departure
*=Session Chair †=Speaker invited, not yet responded.

Keystone Symposia would like to thank the sponsors of this meeting for their generous support:

We gratefully acknowledge additional support for this conference from:

The Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...

Click here to view these companies

It is now widely recognized that the immune microenvironment of a tumor provides critical support in determining its progression versus dormancy or destruction. To gain immune benefits the tumor must evolve mechanisms of immune escape. Study of this crucial process requires cross-fertilization between molecular cell biologists and tumor immunologists who do not tend to interact. This problem is also integrated with the problem of cancer inflammation that has captured the attention of tumor biologists focused on transgenic mouse models and clinical settings. Thus, we propose a unique conference – the first of its kind – to integrate perspectives from a diverse set of researchers in cancer, immunology, and molecular therapeutics and to focus specifically on immune escape and tumor-induced immune suppression as a multidisciplinary problem. Cancer is initiated by the accumulation of genetic and epigenetic changes in a normal cell, but its progression depends on the stromal and immune microenvironment of the initiated cell. While intrinsic signals within the initiated cell drive neoplastic transformation and genomic plasticity, extrinsic signals delivered by immune cells are critical in dictating whether progression versus dormancy or destruction of an initiated lesion takes place, and also whether metastasis may occur. The high degree of genomic plasticity in cancer cells permits them to develop sophisticated ways to prevent the immune system from recognizing and eliminating tumor cells. It has become increasingly clear in recent years that abnormalities in the immune system that are induced by tumors not only hamper natural anti-tumor immune surveillance but also limit the efficacy of immunotherapy and even traditional chemotherapy and radiotherapy. Thus, tumor-induced immune abnormalities may not only impact the clinical course of disease but also the prospects for its therapeutic management. Recent results indicate that we are on the verge of a real breakthrough in our understanding of how tumors thwart the immune system and how correcting immune escape could vastly improve cancer therapy. However, at present the available mechanistic information presents a somewhat convoluted picture that includes some seemingly contradictory elements. While this situation is a natural stage of development in the field, there is nevertheless a pressing need to define key questions and organize their development in coherent ways that can speed improvements in cancer therapy.

Molecular and Cellular Biology of Immune Escape in Cancer (J6)